FDA Approves Ambelvist (gadoquatrane) Low-Dose Contrast Agent for Magnetic Resonance Imaging
RegulatoryapprovedAmbelvistPositive
AI Analysis
Summary
Bayer announced FDA approval of Ambelvist (gadoquatrane), a new intravenous macrocyclic gadolinium-based contrast agent for magnetic resonance imaging.
Outcome Details
FDA approved gadoquatrane (Ambelvist), a macrocyclic gadolinium-based contrast agent for intravenous use in MRI
Importance:8/10
Sentiment:
0.80
FDA approvalcontrast agentMRIgadoliniumBayermedical imaging
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 15, 2026 8:06 AM